The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease

Sodium –glucose cotransporter 2 (SGLT2) inhibitors are an antihyperglycemic drug with diuretic action. We recently reported that the SGLT2 inhibitor dapagliflozin ameliorates extracellular volume expansion with...

Source: Diabetology and Metabolic Syndrome - May 1, 2020 Category: Endocrinology Authors: Ken Ohara, Takahiro Masuda, Masato Morinari, Mari Okada, Atsushi Miki, Saki Nakagawa, Takuya Murakami, Kentaro Oka, Maki Asakura, Yasuharu Miyazawa, Akito Maeshima, Tetsu Akimoto, Osamu Saito and Daisuke Nagata Tags: Research Source Type: research